Bacterial Eavesdropping for Fast Antibiotic Susceptibility Testing
SoundCell technology aims to revolutionize antimicrobial susceptibility testing by reducing diagnostic time to under 1 hour, improving treatment outcomes and lowering healthcare costs.
Projectdetails
Introduction
Antimicrobial resistance (AMR) is a global health problem, endangering millions of lives. Rapid Antimicrobial Susceptibility Testing (AST) plays a crucial role in determining the type and concentration of antibiotics required to inhibit the growth of a pathogen.
Current Challenges
However, the major issue with the current ASTs is the slow diagnostics, ranging from 24 hours to a few days. This delay leads to mis-prescriptions and/or over-prescriptions, thus severely impacting treatment outcomes.
SoundCell Technology
At SoundCell, we developed SoundCell technology, a breakthrough technique that reduces the AST time from a few days to less than 1 hour. It is a graphene-based biosensor technology that uses nanomechanical vibrations of ultrathin micron-sized graphene drums to detect the motion of a single bacterium.
Motion Detection
We demonstrated that the motion of alive and dead bacteria is different when adhered to the graphene sensors, and we can correlate such changes to antibiotic susceptibility.
Project Goals
During the EICT, we will mature SoundCell technology into a high-throughput, cost-effective AST. Our goals include:
- Developing high-volume manufacturing methods.
- Engineering a user-friendly low-cost prototype readout system.
- Validating our AST prototype in 2 clinical labs through testing of a variety of pathogenic clinical isolates.
- Benchmarking the speed and sensitivity of our platform against other AST techniques.
- Establishing our exploitation strategy and regulatory roadmap.
- Developing and executing the business model.
- Engaging stakeholders.
Expected Outcomes
SoundCell technology will directly lower healthcare expenses by shortening hospital stays with fewer lab and diagnostic tests. It will also improve clinical outcomes for patients by reducing recovery time, secondary complications, and mortality.
Intellectual Property
We have filed 2 patent applications and envision another 4 patents over the project duration.
Financial Forecast
By 2030, we forecast revenues of 17 million and employment for up to 60 personnel.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.499.143 |
Totale projectbegroting | € 2.499.143 |
Tijdlijn
Startdatum | 1-11-2023 |
Einddatum | 31-10-2026 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- SOUNDCELL B.V.penvoerder
Land(en)
Vergelijkbare projecten binnen EIC Transition
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
AUTOMATED CLINICAL PLATFORM FOR PERSONALIZED ANTIBIOTHERAPY IN CRITICAL UNITS BASED ON SURFACE ENHANCEMENT RAMAN SPECTROSCOPYACU-SERS aims to revolutionize antibiotic dosing in sepsis patients by providing a fast, automated, and cost-effective system for therapeutic drug monitoring, enhancing clinical outcomes and commercial viability. | EIC Transition | € 2.499.997 | 2024 | Details |
Rapid Affordable Microbiota Analysis at the point of NeedBforCure's RAMAN project aims to develop a rapid, affordable microbiota analysis device for point-of-need testing, enhancing health and production outcomes in various sectors. | EIC Transition | € 2.466.223 | 2024 | Details |
AUTOMATED CLINICAL PLATFORM FOR PERSONALIZED ANTIBIOTHERAPY IN CRITICAL UNITS BASED ON SURFACE ENHANCEMENT RAMAN SPECTROSCOPY
ACU-SERS aims to revolutionize antibiotic dosing in sepsis patients by providing a fast, automated, and cost-effective system for therapeutic drug monitoring, enhancing clinical outcomes and commercial viability.
Rapid Affordable Microbiota Analysis at the point of Need
BforCure's RAMAN project aims to develop a rapid, affordable microbiota analysis device for point-of-need testing, enhancing health and production outcomes in various sectors.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
GAAFSTE: GrAfeen nAnosensoren voor Fast (snelle) antibiotica Susceptibiliteit TEstDit project ontwikkelt een snel prototype voor antibiotica susceptibiliteitstests, dat binnen 2 uur resultaten levert, om de effectiviteit van antibiotica te optimaliseren en resistentie tegen te gaan. | Mkb-innovati... | € 275.555 | 2022 | Details |
Rapid chip-based detection of antibiotic resistancesDeveloping ResisCHIP, a rapid RNA diagnostic tool for bacterial infections, to enhance treatment selection and combat antimicrobial resistance within 2 hours from blood samples. | ERC Proof of... | € 150.000 | 2022 | Details |
A Novel Rapid Antibiotic Susceptibility Testing Device to Enhance Hospital Patient Outcomes - KAIROSKAIROS ontwikkelt een sneltestapparaat voor antibiotica-gevoeligheid om de behandeling van infecties te versnellen en patiëntresultaten te verbeteren. | 1.1 - Het ve... | € 1.228.072 | 2024 | Details |
self-PoweRed cONductimeter for digiTalization of rapid mOlecular diagnosticsPRONTO aims to develop a low-cost, self-powered conductimetric sensor for rapid, sensitive detection of infectious diseases, making advanced testing accessible in low- and medium-income countries. | ERC Proof of... | € 150.000 | 2023 | Details |
RADARRADAR ontwikkelt een platformtechnologie voor snelle en nauwkeurige diagnose van urineweginfecties en antibioticaresistentie. | Mkb-innovati... | € 168.350 | 2021 | Details |
GAAFSTE: GrAfeen nAnosensoren voor Fast (snelle) antibiotica Susceptibiliteit TEst
Dit project ontwikkelt een snel prototype voor antibiotica susceptibiliteitstests, dat binnen 2 uur resultaten levert, om de effectiviteit van antibiotica te optimaliseren en resistentie tegen te gaan.
Rapid chip-based detection of antibiotic resistances
Developing ResisCHIP, a rapid RNA diagnostic tool for bacterial infections, to enhance treatment selection and combat antimicrobial resistance within 2 hours from blood samples.
A Novel Rapid Antibiotic Susceptibility Testing Device to Enhance Hospital Patient Outcomes - KAIROS
KAIROS ontwikkelt een sneltestapparaat voor antibiotica-gevoeligheid om de behandeling van infecties te versnellen en patiëntresultaten te verbeteren.
self-PoweRed cONductimeter for digiTalization of rapid mOlecular diagnostics
PRONTO aims to develop a low-cost, self-powered conductimetric sensor for rapid, sensitive detection of infectious diseases, making advanced testing accessible in low- and medium-income countries.
RADAR
RADAR ontwikkelt een platformtechnologie voor snelle en nauwkeurige diagnose van urineweginfecties en antibioticaresistentie.